Shire (SHPG) Stock Price, News & Analysis

Company Overview

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $179.20 to $179.20
• 50-Day Range: $179.20 to $179.20
• 52-Week Range: $123.73 to $182.47
• Volume: N/A
• Average Volume: 2.21 million shs
• Market Capitalization: $54.71 billion
• P/E Ratio: 11.83
• Dividend Yield: 0.19%
• Price Target: N/A
• Consensus Rating: N/A

SHPG Stock Analysis - Frequently Asked Questions

How were Shire's earnings last quarter?

Shire plc (NASDAQ:SHPG) released its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.58 by $0.28. The company's revenue for the quarter was up 5.4% compared to the same quarter last year.

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shire investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Meta Platforms (META), Intel (INTC), Cisco Systems (CSCO), NVIDIA (NVDA) and Biogen (BIIB).

Company Calendar

• Last Earnings: 4/26/2018
• Today: 12/22/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SHPG
• CUSIP: N/A
• CIK: 936402
• Web: www.shire.com
• Phone: 353-1609-6000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $15.15
• Trailing P/E Ratio: 11.83
• Forward P/E Ratio: 11.88
• P/E Growth: 1.54
• Net Income: $4.27 billion
• Net Margins: 30.63%
• Pretax Margin: N/A
• Return on Equity: 12.70%
• Return on Assets: 7.06%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 0.92
• Quick Ratio: 0.51

Sales & Book Value

• Annual Sales: $15.16 billion
• Price / Sales: 3.61
• Cash Flow: $22.71 per share
• Price / Cash Flow: 7.89
• Book Value: $119.43 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 305,280,000
• Free Float: N/A
• Market Cap: $54.71 billion
• Optionable: Optionable
• Beta: 0.87